The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)
Tóm tắt
The aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (SOC), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (The Schizophrenia Trial of Aripiprazole [STAR] study [NCT00237913]). This open-label, 26-week, multi-centre, randomised study compared aripiprazole to SOC (olanzapine, quetiapine or risperidone) in patients with schizophrenia (DSM-IV-TR criteria). The primary effectiveness variable was the mean total score of the Investigator Assessment Questionnaire (IAQ) at Week 26. The outcome research variables included the Arizona Sexual Experience scale (ASEX). This along with the data collected on serum prolactin levels at week 4, 8, 12, 18 and 26 will be the focus of this paper. A total of 555 patients were randomised to receive aripiprazole (n = 284) or SOC (n = 271). Both treatment groups experienced improvements in sexual function from baseline ASEX assessments. However at 8 weeks the aripiprazole treatment group reported significantly greater improvement compared with the SOC group (p = 0.007; OC). Although baseline mean serum prolactin levels were similar in the two treatment groups (43.4 mg/dL in the aripiprazole group and 42.3 mg/dL in the SOC group, p = NS) at Week 26 OC, mean decreases in serum prolactin were 34.2 mg/dL in the aripiprazole group, compared with 13.3 mg/dL in the SOC group (p < 0.001). The study findings suggest that aripiprazole has the potential to reduce sexual dysfunction, which in turn might improve patient compliance.
Tài liệu tham khảo
Hummer M, Huber J: Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin. 2004, 20: 189-197. 10.1185/030079903125002865.
Mah PM, Webster J: Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002, 20: 365-373. 10.1055/s-2002-36709.
Klibanski A, Neer RM, Beitins IZ, et al: Decreased bone density in hyperprolactinemic women. N Engl J Med. 1980, 303: 1511-1514.
Smith S, Gillam A: Sexual dysfunction – the forgotten taboo. Mental Health Nurs. 2005, 25: 6-9.
Gopalakrishnan R, Jacob KS, Kuruvilla A, Vasantharaj B, John JK: Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial. Am J Psychiatry. 2006, 163: 494-499. 10.1176/appi.ajp.163.3.494.
Beasley CM, Tollefson G, Tran P, et al: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996, 14: 111-123. 10.1016/0893-133X(95)00069-P.
Schulz E, Fleischhaker C, Remschmidt HE: Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. J Child Adolesc Psychopharmacol. 1996, 6: 119-131.
Crawford AM, Beasley CM, Tollefson GD: The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 1997, 26: 41-54. 10.1016/S0920-9964(97)00036-4.
Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG: Quetiapine in patients with schizophrenia. A high and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997, 54: 549-557.
Arvanitis LA, Miller BG: Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997, 42: 233-246. 10.1016/S0006-3223(97)00190-X.
Knegtering H, Moolen van der AE, Castelein S, et al: What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?. Psychoneuroendocrinology. 2003, 28 (Suppl 2): 109-123. 10.1016/S0306-4530(02)00130-0.
Bobes J, Garc A-Portilla MP, Rejas J, et al: Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther. 2003, 29: 125-147. 10.1080/713847170.
Dossenbach M, Dyachkova Y, Pirildar S, et al: Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry. 2006, 21: 251-258. 10.1016/j.eurpsy.2005.12.005.
El-Sayeh HG, Morganti C: Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2006, CD004578-2
NICE: Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. 2002, London, United Kingdom: National Institute for Clinical Excellence
Voruganti L, Cortese L, Owyeumi L, et al: Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res. 2002, 57: 201-208. 10.1016/S0920-9964(01)00309-7.
Sebastian CS, Glazer W, Buckley PF: Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. Curr Med Chem. 2004, 11: 329-342. 10.2174/0929867043456025.
Kerwin R, Millet B, Herman E, et al: A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry. 2007,
McGahuey CA, Gelenberg AJ, Laukes CA, et al: The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000, 26: 25-40. 10.1080/009262300278623.
Food & Drug Administration: Supplementary suggestions for preparing an integrated summary of safety information in an original NDA submission and for organizing information in Periodic Safety Updates. FDA Division of Neuropharmacological Drug Products. Rockville, MD. February 27, 1987
Tandon R, Devellis RF, Han J, et al: Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res. 2005, 136: 211-221. 10.1016/j.psychres.2005.05.006.
Cutler AJ: Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology. 2003, 28 (Suppl 1): 69-82. 10.1016/S0306-4530(02)00113-0.
Rethink : A question of choice. London. 2002
Weiden PJ, Miller AL: Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract. 2001, 7: 41-47. 10.1097/00131746-200101000-00005.
Fakhoury WK, Wright D, Wallace M: Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol. 2001, 16: 153-162. 10.1097/00004850-200105000-00004.
Hofer A, Kemmler G, Eder U, et al: Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004, 65: 932-939.
Clayton AH: Sexual function and dysfunction in women. Psychiatr Clin North Am. 2003, 26: 673-682. 10.1016/S0193-953X(03)00043-1.
Compton MT, Miller AH: Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull. 2002, 36: 143-164.
Wang PS, Walker AM, Tsuang MT, et al: Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry. 2002, 59: 1147-1154. 10.1001/archpsyc.59.12.1147.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/8/95/prepub